Brokerages forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($1.33) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings. The lowest EPS estimate is ($1.44) and the highest is ($1.24). Ascendis Pharma A/S posted earnings per share of ($0.87) during the same quarter last year, which suggests a negative year over year growth rate of 52.9%. The business is expected to report its next quarterly earnings report on Wednesday, April 1st.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year earnings of ($4.53) per share for the current financial year, with EPS estimates ranging from ($4.76) to ($3.92). For the next year, analysts expect that the company will post earnings of ($4.93) per share, with EPS estimates ranging from ($7.01) to ($1.68). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Ascendis Pharma A/S.
ASND has been the topic of several recent research reports. Leerink Swann reiterated an “outperform” rating and issued a $152.00 price objective (up from $140.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. BidaskClub lowered shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 12th. Wedbush reiterated a “buy” rating and issued a $186.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, November 19th. Finally, Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus price target of $150.50.
Institutional investors have recently added to or reduced their stakes in the stock. Laurion Capital Management LP purchased a new stake in shares of Ascendis Pharma A/S in the 2nd quarter worth about $1,869,000. Flinton Capital Management LLC raised its stake in Ascendis Pharma A/S by 6.7% in the 2nd quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 144 shares during the last quarter. Camber Capital Management LP raised its stake in Ascendis Pharma A/S by 51.2% in the 2nd quarter. Camber Capital Management LP now owns 650,000 shares of the biotechnology company’s stock valued at $74,848,000 after purchasing an additional 220,000 shares during the last quarter. Atria Investments LLC raised its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Atria Investments LLC now owns 4,466 shares of the biotechnology company’s stock valued at $509,000 after purchasing an additional 417 shares during the last quarter. Finally, International Biotechnology Trust PLC raised its stake in Ascendis Pharma A/S by 87.0% in the 2nd quarter. International Biotechnology Trust PLC now owns 25,800 shares of the biotechnology company’s stock valued at $2,969,000 after purchasing an additional 12,000 shares during the last quarter.
Shares of Ascendis Pharma A/S stock traded up $2.49 on Wednesday, hitting $116.24. The company’s stock had a trading volume of 144,737 shares, compared to its average volume of 299,879. Ascendis Pharma A/S has a 52-week low of $54.67 and a 52-week high of $133.96. The company has a quick ratio of 15.75, a current ratio of 15.74 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $109.71 and a 200-day moving average price of $112.61. The company has a market capitalization of $4.85 billion, a P/E ratio of -31.08 and a beta of 0.63.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Recommended Story: How can investors benefit from after-hours trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.